Twice Daily Compared to Three Times Daily Hydrocortisone in Prepubertal Children with Congenital Adrenal Hyperplasia.

Overview

abstract

INTRODUCTION: Glucocorticoid therapy in children with congenital adrenal hyperplasia (CAH) must be finely balanced between optimizing adrenal control and minimizing side effects. Twice (BID) rather than three times (TID) daily hydrocortisone may provide similar adrenal control and reduce metabolic risk. We compared BID and TID regimens with respect to adrenal control, growth, and metabolic effects. METHODS: A retrospective chart review (n=128 visits, 36 individual patients) of prepubertal children with classical CAH was conducted at a tertiary care center between March 2007 and February 2020. Adrenal control, growth, and metabolic data were extracted in those taking hydrocortisone BID versus TID. Univariate generalized estimating equations models were performed to analyze the effect of dose frequency on outcomes of interest. RESULTS: Overall, we found no difference in adrenal control (8% v. 18% poor control) or testosterone levels (9.65 ng/dL v 7.62 ng/dL) between the BID versus TID groups. We detected no difference in growth velocity (6.86 v. 6.32 cm/year) or bone age advancement (11.3 v. 5.91 months) between the groups. There was no difference in daily steroid dose (12.1 v. 11.7 mg/m2/day), BMI z-score (0.43 v. 0.31), or systolic blood pressure percentile (65.5 v. 61.7). CONCLUSION: BID dosing provides similar adrenal control and does not appear to impact growth or bone age advancement. On the other hand, TID dosing does not appear to increase the metabolic side effect profile in this age group. Dosing should be patient-centered with individualized consideration.